Venetoclax is a small molecule BH3 mimetic drug that selectively binds BCL2 and inhibits its prosurvival function.20,21 Since initial FDA approval of venetoclax for treatment of chronic lymphocytic leukaemia (CLL) patients with 17p chromosomal deletion,22 additional combination regimens have been approved.23,24 Novel combinations are needed to improve responses in NHL, where single agent venetoclax has limited activity.25 Here we tested the efficacy of SBI-0640756 (SBI-756 hereafter) in NHL cell lines, alone and in combination with venetoclax. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.